← All Cocrystal Pharma, INC filings

Cocrystal Pharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
COCP
Cocrystal Pharma, INC
10-K: Cocrystal Pharma Faces Going Concern Doubt, Clinical Setbacks
Cocrystal Pharma's annual report highlights significant financial challenges, including a going concern doubt and a failed Phase 2a influenza trial, despite progress in other antiviral programs.
NASDAQ
COCP
Cocrystal Pharma, INC
10-K: Cocrystal Pharma Reports Annual Results, Faces Going Concern Uncertainty Amidst Antiviral Development
Cocrystal Pharma's annual report reveals ongoing antiviral therapeutic development efforts alongside financial challenges and a going concern qualification.
NASDAQ
COCP
Cocrystal Pharma, INC
10-K/A: Cocrystal Pharma Files Amended Annual Report on Form 10-K/A
Cocrystal Pharma has filed an amendment to its annual report to include information required in Part III, which was not included in the original filing.
NASDAQ
COCP
Cocrystal Pharma, INC
10-K: Cocrystal Pharma Implements Code of Ethics and Insider Trading Policy
Cocrystal Pharma has formalized its ethical standards and insider trading rules with the adoption of a new Code of Ethics and Insider Trading Policy.